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Summary A 15 month old boy with a stage IV right suprarenal gland neuroblastoma showed a number of
raised biochemical parameters, whilst catecholamines and skeletal survey were normal. Treatment with
peptichemio failed to give a clinical response.
Histological evidence of neuroblastoma infiltration in the bone marrow aspirate was absent. Immuno-
fluorescence on sedimented cells was negative using antibody UJ223.8, PI153/3 and HI 1; only UJ308 and to a
lesser extent UJ13A gave positive results. After 21 days, however, the same cells in culture showed highly
differentiated dendritic processes.
Thirty-seven percent metaphases from bone marrow aspirate showed the following karyotype 45XY, del (1)
(p32), and two markers. Marl=der (2) t (2; 2) (2qter-.2ql4::2p24-.2qter). Mar2=der (15) t (15; 2)
(l5qter 15p1 ::2pl 1 -*2pter).
Treatment with methotrexate reduced the aberrant mitoses rate to 2%. N-myc in situ hybridisation showed
significant signal on both markers confirming the cytogenetic interpretation.
Peripheral blood lymphocytes at 72 h showed a higher level of breaks per cell than control. After treatment
with aphidicolin (APC) or methotrexate (MTX) for the last 24h, to induce fragile sites, the incidence of
breaks per cells was increased. Moreover 11.4% of APC-induced breaks were in lp31-32 (mean of normal
controls=2.3%). The mother presented an increased sensitivity to the inducibility of fragile sites, while the
father's lymphocytes showed values within the control range.
The genetic changes produced by the abnormalities on chromosomes 1 and 2 might be related to tumour
progression. Furthermore this is the first description of correlation between a high frequency of fragile site
lp3l-32 induced by APC in the patient's lymphocytes and deletion of lp32 in tumour cells. The
interpretation of these findings and of other similar correlations needs further study.
The clinical outcome of neuroblastoma patients is good for
early stages (I-II) with minimal disease below the age of 1
year and for stage IV-S. However stages III and IV over 1
year of age experience a very poor prognosis. Shimada et al.
(1984) first explored the relationship between morphologic
differentiation and prognosis. Schwab et al. (1983) related
N-myc amplification with morphologic differentiation, and
Brodeur and Seeger (1986) produced clinical evidence for a
connection between N-myc amplification and prognosis. The
gene changes presumed to induce or to contribute to tumour
initiation and progression may be associated with cytogenetic
abnormalities as already reported for other tumours (Klein
1983; Canaani et al., 1984). At a simple level of analysis,
both Look et al. (1984) and Gansler et al. (1986) related the
DNA content of neuroblastoma cells to prognosis. A more
favourable clinical outcome was associated with a hyper-
diploid situation. Kaneko et al. (1987) attempted to relate
various karyotypic patterns, characteristic of neuroblastoma,
to prognosis.
Partial monosomy of the short arm of chromosome 1 was
reported as the most common aberration in human neuro-
blastomas (Brodeur et al., 1981; Gilbert et al., 1984). Recently
it has been postulated that this chromosomal alteration
might be typical of patients at stages III and IV (Franke et
al., 1986). On the same arm of chromosome 1, three
common fragile sites were mapped in lp22, lp3l-32, 1p36
(Berger et al., 1985). Hecht and Glover (1984) showed that
the localisation of fragile sites and tumour breakpoints in the
same chromosomal bands is not random.
The amplification of the oncogene N-myc characterizes the
most advanced stages of the disease (III, IV). This gene has
been mapped on chromosome 2 (2p23-24) (Schwab et al.,
1983), however, its amplification is often localised in homo-
geneously staining regions (HSR) on different chromosomes,
or in double minutes (dms).
Here we describe the cytogenetic and immunochemical
characterization of a case of disseminated neuroblastoma in
a 15 month old boy.
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This report produces evidence of (i) a translocation involv-
ing 2p24, (ii) increased expression of fragile site lp31-32 in
the patient's normal lymphocytes corresponding to a deletion
in the tumour cells, an association described for the first
time at this site, (iii) high incidence of fragile sites in normal
lymphocytes, in both the patient and his mother.
Patient and methods
Case report
MF was a 15 month old boy when the diagnosis of stage IV
neuroblastoma arising from the right suprarenal region was made at
the end of January 1987. The symptoms at presentation included
anaemia, fatigue, weight loss and diarrhoea. At the 17th week of
pregnancy cytogenetic analysis by aminocentesis, performed because
of the advanced age of the mother (42), gave a normal karyotype.
At birth an ultrasound (U/S) analysis confirmed the clinical evidence
of a 3 cm mass on/above the right kidney. This regressed within a
few weeks. At the age of 14 months, however, he presented with an
abdominal mass with a diameter of 14cm involving the great vessels
and infiltrating the lymphnodes. Skeletal survey and urinary levels of
catecholamine metabolites were within normal ranges. Histology on
a needle biopsy and on a laparotomy sample showed neuroblastoma
cells. Other biochemical investigations indicated abnormal erythro-
cyte sedimentation rate (80mmh-1), neuron specific enolase (NSE)
(120 ngml -1), ferritin (225 raising to 1,440 ngml 1) lactate dehydro-
genase (2,130 IUl-1).
Chemotherapy was performed according to de Bernardi et al.
(1982). Seven cycles of peptichemio as the main drug, followed by
adriamycin, vincristine and cyclophosphamide were administered
from February to August 1987. No clinical response was noted, as
evaluated by computerized tomography scan, X-ray, U/S and clini-
cal assessment. The child died at the end of August 1987. A post-
mortem confirmed the diagnosis of neuroblastoma.
Immunofluorescence
Tumour cells from a bone marrow aspirate were sedimented
on a Lymphoprep (Nyegaard, Norway) gradient at 800g for
20 min at 20°C. Cells were washed twice in RPMI-1640
medium. One million cells were incubated for 20 min at
room temperature with 20,l of 4 antibodies specific for
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neuroblastoma UJ308, UJl3A, UJ223.8, PI 153/3, HI 1
(Sugimoto et al., 1984). UJ308 antibody was used as positive
control for its ability to bind bone marrow cells. The
negative control was treated only with the second antibody.
Following two washes in PBS-azide (1 mM) a second incuba-
tion was performed for 20 min at room temperature with
40 4ul FITC-labelled goat anti-mouse immunoglobulin anti-
body (Cappell, USA). Two further washes in PBS-azide were
performed before analysing the fluorescence under a Leitz
Dialux 22 UV-light microscope or on a FACS-analyser
(Becton-Dickinson, USA) flow cytometer.
Cell culture
Tumour cells were harvested from the bone marrow by
gradient, as described above. Washed nucleated cells,
approximately 5 x 106, were seeded on 25cm2 flasks pre-
treated with collagen for 3 h and then transferred into new
flasks. Cultures were performed at 37°C in a humidified
incubator in the presence of 5% C02, using RPMI 1640
supplemented with 10% v/v heat-inactivated foetal calf
serum, 2 mM L-glutamine, 2 g 1-1 Na-bicarbonate, 5 mM
HEPES, 1% v/v non-essential amino acids, 100 IUml-1
penicillin and streptomycin. All culture reagents were from
Flow Ltd., UK.
Cytogenetics
Bone marrow cells were cultured for 1, 24 or 48 h including
1 h in the presence of 2 pg colchicine ml - (Sigma, USA)
and then harvested (Table I). A parallel sample was synchro-
nised with methotrexate (MTX) (Lederle, UK) as described
by Hagemeyer et al. (1979) and harvested at 24h.
Whole blood cultures from the patient and his parents
were performed by stimulation with 2% v/v PHAm (Difco,
USA) for 72h. Some cultures were treated for the last 24h
with 0.04 pgml-1 aphidicolin (APC) (Serva, FRG) or 10 ug
MTXml- 1 to induce the expression of common fragile sites.
Chromosomes were obtained by standard techniques, and
banded by mild trypsin treatment (Seabright,. 1971). One
hundred metaphases were observed for each culture.
In vitro hybridisation was performed with 2 kbp N-myc
Eco RI probe, labelled by nick translation using 3H-dCTP
and 3H-dTTP (Amersham, UK) to a specific activity of
3.5 x I07 dpmjg-l. We used the method of Harper and
Saunders (1981) as modified by Bartram et al. (1983). Slides
were coated by NTB2 emulsion (Kodak, USA) and exposed
in darkness at 4°C for 15-21 days. After development and
fixation, chromosomes were stained with Wright's solution
(Chandler & Yunis, 1978).
Grain location was reported on a chromosome ideogram
(Yunis, 1981). x2 analysis was performed to evaluate statisti-
cal significance of grain distribution on chromosomes.
weakly positive for UJ13A, and positive for UJ308. The
antibodies were able to bind subsequent samples of neuro-
blastoma and the technique was considered adequate as
shown by the UJ308 reactivity. Even though histology and
three specific antibodies gave a genuine negative result, the
UJ13A reactivity suggested a neuroblastoma infiltration in
the bone marrow.
In order to verify the presence of neuroblastoma cells
infiltrating the bone marrow with a different approach, we
attempted to grow them in culture. Figure 1 shows the
tumour cells at the 21st day after seeding. Various neuronal-
like islets were evident on a fibroblast layer. Many long
dendritic processes raised from the central nucleous, connect-
ing other islets. This morphological appearance has been
previously described for other primary neuroblastomas in
short term culture (Biedler et al., 1978; Ito et al., 1987). This
was conclusive evidence of neuroblastoma infiltration in the
bone marrow.
Cytogenetic studies
No constitutional aberrations were found in chromosomes
from lymphocytes of the patient or his parents.
In bone marrow cells two lines were detected, as indicated
in Table I. One with normal karyotype and a second line
(see Figure 2), with a karyotype of 45XY, del (1) (p32), and
2 markers that we interpreted as Mar 1=der (2) t (2; 2)
(2qter-+2ql4::2p24-+2qter). Mar 2=der (15) t (15; 2)
(l5qter-+ 15pl1::2pl1-+2pter). Three percent of these meta-
phases showed also dms.
Treatment of bone marrow cells with 5 pg MTXml 1 led
to the unexpected disappearance of almost all cytogenetically
abnormal cells (Table I). The results of the in situ hybridisa-
tion with the N-myc probe are shown in Table II. A
significant number of grains was localised both in the long
arms of marker 1, supposed to contain 2p23-24, and in the
short arm of marker 2, supposed to be the short arm of
chromosome 2 (Figure 3). The data confirm the cytogenetic
interpretation of the markers. A very high sensitivity to APC
and MTX was found in the patient and his mother, while
the father showed values comparable to those of our
controls, as shown in Table III. A particularly interesting
finding was the increased expression of fragile site lp3l-32
in the patient. Twenty-three out of 202 aberrations (11.4%)
were located in lp3l-32, while they were 4 out of 174
(2.3%) in normal controls. The distribution of other fragile
sites in the patient (data not shown) was not dissimilar from
normal controls (Tedeschi et al., 1987). In particular the
expression of fragile site 2p24 was not increased (2 out of
202, i.e. 0.99%, in the patient; 3 out of 174, i.e. 1.72%, in
normal controls) even though that area could have been
involved in the formation of marker 1. The fragile site lp3l-
32 in patient's normal cells coincides with the breakpoint in
tumour cells.
Results
Bone marrow analysis
Bone marrow aspirates from the right and the left anterior
iliac crests were immediately tested for neuroblastoma infilt-
ration by the indirect immunofluorescence technique. Cells
were negative for antibodies UJ223.8, PI 153/3 and H-Il;
Table I Cytogenetic analysis of bone marrow cells
Total number
Abnormal Normal of metaphases
metaphasesa metaphases studied
1 h culture 37 63 100
24h culture 38 62 100
24h culture+MTX 2 98 100
48h culture 49 51 100
aPresence of Marl and Mar2 and l.
Figure 1 Neuroblastoma cells after three weeks of culture. The
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Figure 2 G-banded karyotype of a tumour cell derived from bone marrow of the patient.
Table H N-myc in situ hybridisation of markers in Figure 3
Grains
Metaphases
studied Expected Observed x2a p
Tumour cells
Marl, long arm 40 11 20/188 (10.6%) 7.4 <0.01
Mar 1 in 2p23-24 40 - 9/20 (45.0%) - -
Mar 2, short arm 40 4.3 13/188 (6.9%) 17.4 <0.01
Mar2 in 2p23-24 40 - 8/13 (61.5%) -
Normal cells'
2p 85 8 36/371 (9.7%) 24.5 <0.01
2p in 2p23-24 85 - 16/36 (44.4%) - -
aThe expected value was calculated according to the length of the chromosome arm
(ISNC, 1981). bNormal metaphases from PHA-stimulated peripheral blood lymphocytes.
Discussion
Since the data presented in this report demonstrate that
neuroblastoma cells were present in the patient's bone
marrow aspirate (Figure 1), we are justified in considering
the abnormal mitoses described as belonging to these abnor-
mal cells. The points of interest shown by the cytogenetic
analysis are:
(i) One of the translocations described (Mar 1) occurred
near the site of the N-myc oncogene at 2p23-24,
which is possibly relevant because of the N-myc
amplification reported for neuroblastoma.
(ii) The normal lymphocytes of the patient expressed a
chromatid fragile site in lp3l-32 corresponding to the
deletion found in the tumour cells.
(iii) The patient and his mother both expressed an
increased incidence of fragile sites. This may possibly
be relevant for the transmission of the predisposition
to tumour development.
Since neuroblastoma cells have a heterogeneity of reacti-
vity, a panel of 4 monoclonal antibodies was used for the
immunofluorescence. This method is usually very reliable
and sensitive for the identification of neuroblastoma cells
since the reactivity of only one antibody may be sufficient
for the diagnosis (Kemshead et al., 1983; Sugimoto et al.,
1984; Kemshead, 1984). The UJ13A positivity was the only
immediate suggestion of neuroblastoma infiltration in the
bone marrow. In fact only after 21 days did the cultured
cells show the typical morphology of neuroblastoma (Figure
1). This is not the only report of neuroblastoma infiltration
BJC-C
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Table III Aberrations found in 100 metaphases from peripheral blood lymphocytes
untreated or exposed for the last 24h to aphidicolin (APC) or methotrexate (MTX)
Aberrations Chromatid Chromosome Chromatid Chromosome
Treatment Subject per cell breaks breaks gaps gaps
NONE Patient 0.18 10 4 2 2
NONE Mother 0.18 12 0 6 0
NONE Father 0.04 2 0 2 0
NONE Controls 0.04a 6 20 28 10
APC Patient 2.02 152 3 44 3
APC Mother 1.20 83 15 22 0
APC Father 0.28 15 10 3 0
APC Controls 0.16a 62 20 52 52
MTX Patient 0.46 34 2 8 2
MTX Mother 0.74 65 8 0 1
MTX Father 0.09 5 1 3 0
MTX Controls 0.25a 114 48 108 34
aMean value evaluated on 1,200 metaphases from 12 donors. The s.d. were respectively
0.03, 0.07, 0.12 for untreated, APC-treated and MTX-treated cells.
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Figure 3 Cumulative grain distribution on the 2 markers after
in situ hybridisation with N-myc probe on 40 metaphases. See
also Table II.
in the bone marrow with negative histology (Ito et al., 1987).
The cytogenetic analysis and the short-term culture were the
clearest demonstrations of neoplastic infiltration in the bone
marrow, emphasising these types of analysis in parallel to
immunofluorescence and histology. 'Atypical' findings on
this neuroblastoma were the negative results of some anti-
bodies and the sensitivity of tumour cells to MTX, which is
not considered to be a very effective drug for neuroblastoma
cells. This however does not affect the diagnosis of neuro-
blastoma that was in keeping with the NSE result and the
clinical history.
The deletion lp as described here, the frequent presence of
dms and HSR in a near-diploid lineage have been often
described in neuroblastoma by Brodeur et al. (1981), Gilbert
et al. (1984), and Kaneko et al. (1987). Abnormalities of
chromosome lp have been identified in over 2/3 of neuro-
blastoma cases and of the established cell lines, suggesting
that this segment contains important gene(s) for the nervous
system and for neuroblast transformation (Mathew et al.,
1987), according to the '2-hit' hypothesis of Knudson and
Meadows (1980).
Although only few metaphases in the present report had
dms, and none had HSRs with amplified N-myc, they
showed aberrations in the region containing this proto-
oncogene. This has been confirmed by in situ hybridisation.
For this reason we believe that the translocation producing
marker 1 might have been important for the neuroblast
transformation in this child. Recently, another case of
neuroblastoma has been described with specific aberrations
involving chromosome 1 in lp22 and chromosome 2 in 2p24
(Christiansen et al., 1987). Both observations point out that
chromosomal band 2p24 containing N-myc is involved in
aberrations in neuroblastoma.
The predisposition to tumour development may be trans-
mitted in an heritable fashion (Kushner et al., 1986;
McKusick, 1983). We do not know whether the first 'hit'
may be connected with the increased inducibility of the
fragile site lp31-32 in the child. Other cases in individual
patients showing a particular fragile site expression in lym-
phocytes, and an aberration involving the same chromoso-
mal area in the tumour have already been described. For
example an elevated expression of the 7q31.2 fragile site in 2
patients with ANLL and 7q31.2-q36 deletion in tumour
cells. Similarly the increased expression of the 18q21.3 fragile
site has been associated with a translocation t (14; 18)
(q32.3; q21.3) in a patient with follicular lymphoma; and the
fragile site 16q22.1 is related to inv (p13.11 q22.1) on ANLL
tumour cells (Yunis & Soreng, 1984).
The present case is the first report of association between
a breakpoint in a tumour and a fragile site induced by APC.
Our findings further stress the need of more systematic work
on this subject.
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